Verve Therapeutics, Inc.

( )
VERV PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
AMGNAmgen, Inc. 0.48%246.731.5%$893.73m
MRNAModerna, Inc. 3.73%155.540.0%$852.62m
VRTXVertex Pharmaceuticals, Inc. 0.58%288.981.9%$508.85m
GILDGilead Sciences, Inc. -0.03%62.341.0%$477.30m
NVAXNovavax, Inc. 12.49%64.2975.7%$468.89m
REGNRegeneron Pharmaceuticals, Inc. 0.20%596.562.6%$452.80m
ILMNIllumina, Inc. 1.04%193.023.3%$357.64m
SNSSSunesis Pharmaceuticals, Inc. 3.00%3.780.7%$264.24m
BIIBBiogen, Inc. 0.93%212.581.8%$245.16m
BNTXBioNTech SE 2.24%161.030.0%$215.97m
CRSPCRISPR Therapeutics AG 10.68%70.600.6%$192.52m
BMRNBioMarin Pharmaceutical, Inc. 1.62%86.364.2%$117.47m
EXASEXACT Sciences Corp. 7.95%44.4017.7%$102.51m
NTLAIntellia Therapeutics, Inc. 16.98%63.182.2%$99.79m
AXSMAxsome Therapeutics, Inc. 1.40%41.211.8%$99.33m

Company Profile

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan and Burt A. Adelman in 2018 and is headquartered in Cambridge, MA.